Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence.

Pioglitazone or placebo co-administered with interferon β-1α to patients with relapsing-remitting multiple sclerosis showed no clinical improvement or adverse events through expanded disability status scale, despite a promising significant reduction in gray matter atrophy and a positive trend of lower lesion load in subsequent MRI follow-ups [ 240 ].

also in 11,005 other papers